Extension of the interval between vaccine doses for the BNT162b2 mRNA vaccine was
introduced in the United Kingdom to accelerate population coverage with a single dose. At this …

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein acquired
a D614G mutation early in the pandemic that confers greater infectivity and is now the …

Background Previous infection with SARS-CoV-2 affects the immune response to the first
dose of the SARS-CoV-2 vaccine. We aimed to compare SARS-CoV-2-specific T-cell and …

Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have caused
successive global waves of infection. These variants, with multiple mutations in the spike …

Pronounced immune escape by the SARS-CoV-2 Omicron variant has resulted in many
individuals possessing hybrid immunity, generated through a combination of vaccination and …

In November 2021, Omicron BA.1, containing a raft of new spike mutations, emerged and
quickly spread globally. Intense selection pressure to escape the antibody response produced …

Background: Following a single dose of BNT162b2 mRNA vaccine, higher antibody titres
are observed following prior SARS-CoV-2 infection than in infection-naive individuals, but T-…

Background Both infection and vaccination, alone or in combination, generate antibody and
T cell responses against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). …

Two doses of BNT162b2 mRNA vaccine induces a strong systemic SARS-CoV-2 specific
humoral response. However, SARS-CoV-2 airborne transmission makes mucosal immune …

B.1.1.7 lineage SARS-CoV-2 is more transmissible, leads to greater clinical severity, and
results in modest reductions in antibody neutralization. Subgenomic RNA (sgRNA) is produced …